Attrition In The Pharmaceutical Industry
Download Attrition In The Pharmaceutical Industry full books in PDF, epub, and Kindle. Read online free Attrition In The Pharmaceutical Industry ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Alexander Alex |
| Publisher | : John Wiley & Sons |
| Total Pages | : 370 |
| Release | : 2015-12-02 |
| Genre | : Medical |
| ISBN | : 1118679679 |
With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency. Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition Tackles a problem that adds billions of dollars to drug development programs and health care costs Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition
| Author | : Alexander Alex |
| Publisher | : John Wiley & Sons |
| Total Pages | : 370 |
| Release | : 2015-10-26 |
| Genre | : Medical |
| ISBN | : 1118914341 |
With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency. Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition Tackles a problem that adds billions of dollars to drug development programs and health care costs Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition
| Author | : Kishor B. Barad |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2015 |
| Genre | : |
| ISBN | : |
The Indian Pharma Industry is under a transition phase since the opening up of the country's economy. After IT and BPO industry, the pharmaceutical industry is witnessing the highest level of attrition, as it is growing exponentially. Where skills are relatively scarce, where recruitment is costly or where it takes several weeks to fill a vacancy, attrition is likely to be problematic from a management point of view. This is especially true of situations in which you are losing staff to direct competitors or where customers have developed relationships with individual employees. Gujarat is one of the leading pharmaceutical manufacturing hub of India and thus it was felt to have some short of introspection of its manpower. Therefore this is a humble attempt to study the attrition scenario in the state and identify variables that affects it.
| Author | : James R. Empfield |
| Publisher | : Springer |
| Total Pages | : 176 |
| Release | : 2014-11-27 |
| Genre | : Science |
| ISBN | : 366243914X |
Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.
| Author | : John Ansell |
| Publisher | : CRC Press |
| Total Pages | : 284 |
| Release | : 2016-02-24 |
| Genre | : Business & Economics |
| ISBN | : 1317007727 |
In Transforming Big Pharma John Ansell addresses critically how strategy works in the pharmaceutical industry. The long-standing dearth of new products has led to a growing shortfall in revenues. Ansell assesses the wide range of alternative strategies big pharma companies have been pursuing in recent years in attempting to overcome this. He shows that there is sound evidence to expect the recent upturn in the number of new products reaching the market to go on to greater heights. Chapters assess the complex trends in attrition rates, show how rife spectacular sales underestimation in the industry remains, and explain how conventional wisdom on the chances of product profitability also seriously undersells the industry. The surest route to transforming the prospects for big pharma, Ansell contends, is to step up activity in acquiring and developing new products. This is now realistic because, as he shows, the amount of intellectual property available is much greater than it was a decade ago. Ansell believes that no other strategies have sufficient transformative powers, though they may be useful as a stopgap whilst the sales of forthcoming new products mature. He argues for a reversal of big pharma’s recent cutbacks in R&D and licensing, and re-focussing on new product development. Transforming Big Pharma is intended for those in senior and middle management in the pharmaceutical industry. It will also be valuable to students, as well as to all those dealing with the industry, including biotech companies and those providing services and products to the pharmaceutical industry.
| Author | : Jurgen Moll |
| Publisher | : Humana Press |
| Total Pages | : 388 |
| Release | : 2016-05-01 |
| Genre | : Medical |
| ISBN | : 9781493962785 |
This Methods in Molecular Biology book details current procedures for identifying and validating new drug targets. Includes methods and approaches covering biochemical, cell based, in vivo models and translational methods, as well as relevant case reports."
| Author | : Gerrit Reepmeyer |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 306 |
| Release | : 2006-02-25 |
| Genre | : Business & Economics |
| ISBN | : 379081668X |
The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.
| Author | : Jeffrey S. Handen |
| Publisher | : CRC Press |
| Total Pages | : 324 |
| Release | : 2021-06-30 |
| Genre | : |
| ISBN | : 9781032099941 |
The pharmaceutical industry suffers from an innovation deficit, with clinical attrition and safety-related market-withdrawal rates at the same level as twenty years ago. This book scrutinizes this problem in detail, contrasting the promise of technology and industrialization with the apparent inability of industry to fully realize the tools that ar
| Author | : O. Pelkonen |
| Publisher | : Springer |
| Total Pages | : 306 |
| Release | : 2012-12-16 |
| Genre | : Medical |
| ISBN | : 9783662043851 |
Despite increased spending on research and development, the number of new medicines marketed successfully continues to decline. The Pharmaceutical industry is therefore focussing on ways to reduce attrition by addressing frequent reasons for clinical drug failures very early in the drug discovery process. One of the biggest challenges is the pharmacokinetic (PK) optimisation of drug candidates tailored and predicted to have appropriate absorption, distribution, metabolism and excretion (ADME) characteristics in human. This book describes how traditional pbarmacokinetic approaches and methods are being re-invented' to meet specific needs dictated by the dynamics of the drug discovery process. The book gives an overview of state-of-the-art tools and their use in the decision-making process is discussed by a number of scientists from leading pharmaceutical companies.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 107 |
| Release | : 2014-02-06 |
| Genre | : Medical |
| ISBN | : 0309292492 |
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
